Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to 6119.28%.

  • Sangamo Therapeutics' EBITDA Margin fell 61407900.0% to 6119.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 342.59%, marking a year-over-year decrease of 747900.0%. This contributed to the annual value of 179.88% for FY2024, which is 244000.0% down from last year.
  • Per Sangamo Therapeutics' latest filing, its EBITDA Margin stood at 6119.28% for Q3 2025, which was down 61407900.0% from 97.54% recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' EBITDA Margin registered a high of 21.52% during Q3 2024, and its lowest value of 10712.27% during Q1 2024.
  • Over the past 5 years, Sangamo Therapeutics' median EBITDA Margin value was 205.44% (recorded in 2022), while the average stood at 1966.66%.
  • In the last 5 years, Sangamo Therapeutics' EBITDA Margin crashed by -107236800bps in 2024 and then surged by 103193200bps in 2025.
  • Over the past 5 years, Sangamo Therapeutics' EBITDA Margin (Quarter) stood at 169.58% in 2021, then dropped by -20bps to 203.42% in 2022, then tumbled by -1394bps to 3039.13% in 2023, then surged by 87bps to 399.85% in 2024, then tumbled by -1430bps to 6119.28% in 2025.
  • Its last three reported values are 6119.28% in Q3 2025, 97.54% for Q2 2025, and 460.28% during Q1 2025.